A Ziconopeptide Nanoneedle and its Preparation Method
By preparing ziconopeptide nanoneedles, the cumbersome and traumatic risks of intrathecal injection have been solved, achieving a sustained-release and highly efficient drug delivery method suitable for the treatment of chronic pain, with both safety and flexibility.
Patent Information
- Application Number
- CN202111625336.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-28
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2041-12-28
AI Technical Summary
Existing methods for treating chronic pain with ziconovide mainly rely on intrathecal injection, which is cumbersome, carries risks of trauma, and has low compliance. There is a need for a simple, safe, and efficient method of administration.
Ziconopeptide nanoneedles were prepared by solidifying a hydrogel precursor solution. Ziconopeptide was encapsulated with materials such as distearate phosphatidylethanolamine and lecithin, and modified with materials such as borneol and musk to prepare nanoneedles that can cross the blood-brain barrier. The base thickness was 500 μm to 1 mm, the needle height was 400 μm to 1000 μm, the needle base diameter was 20 to 400 μm, and easy-to-segment lines were engraved.
This technology enables sustained-release administration of ziconopeptide, reducing the risk of trauma, improving the flexibility and compliance of dosing, and allowing for dose control at different stages through segmentation, thereby promoting the drug's efficacy in the cerebrospinal fluid and throughout the body.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical formulation and designs a microneedle, specifically involving a ziconopeptide nanoneedle and its preparation method. Background Technology
[0002] Chronic pain is persistent pain, generally referring to pain lasting more than a month. It is a symptom that accompanies many diseases and affects the physical and mental health of the body. Currently, the number of patients suffering from chronic pain is gradually increasing, and clinical treatment methods are limited, making it one of the major factors troubling human health, and thus it is sometimes referred to as the "cancer that doesn't kill." When conventional painkillers fail to control the pain, treatment can be achieved through intrathecal injection of analgesics such as ziconovide via an implantation pump.
[0003] Ziconotide is a neurotoxic peptide derived from the cone snail, containing 25 amino acids and three disulfide bonds. It is used to treat patients with severe chronic pain who cannot tolerate or respond poorly to other treatments such as intrathecal morphine and systemic analgesics. Ziconotide works by inhibiting N-type calcium channels involved in nociceptive signal transduction; the exact mechanism is not yet fully understood. In the body, pain signal transmission is primarily regulated by neurotransmitter receptors in the dorsal horn of the spinal cord, and calcium ion influx directly or indirectly affects the regulation of neuronal excitability and the release of secondary neurotransmitters. N-type calcium channels are widely distributed throughout the nervous system and its tissues, with a concentrated distribution in the dorsal horn of the spinal cord. Ziconotide selectively acts on N-type calcium channels distributed on the dendrites and axonal terminals of the nervous system, inhibiting the transmission of stimuli to relieve and treat chronic pain.
[0004] Ziconotide, first approved by the FDA under the name "Prialt" on December 28, 2004, and marketed by Tersera Therapeutics Ltd., remains the only FDA-approved calcium channel blocking peptide to date, and all currently marketed formulations are administered via intrathecal injection. Due to the unique nature of its treatment method and procedure, intrathecal injection results in extremely low patient compliance. The entire treatment process requires specialized personnel, is cumbersome, and can easily cause wounds and injection-related fear in patients. Furthermore, intrathecal injection may lead to certain injection complications. This is particularly problematic for diseases requiring long-term treatment, such as chronic pain, which necessitates regular administration and necessitates a simple, safe, efficient, and highly compliant delivery method. Summary of the Invention
[0005] To address the shortcomings of the prior art, this invention provides a ziconopeptide nanoneedle for the treatment of chronic pain, and also proposes a method for preparing the ziconopeptide nanoneedle for the treatment of chronic pain.
[0006] To achieve the above objectives, the present invention provides a nanoneedle containing ziconopeptide for the treatment of chronic pain, characterized in that: the active substance of the nanoneedle is ziconopeptide, and the nanoneedle is prepared by solidifying a hydrogel precursor solution containing ziconopeptide-encapsulated and modified; further characterized in that: the material used to encapsulate the active substance in the nanoneedle is selected from one or more of distearate phosphatidylethanolamine, lecithin, soybean lecithin, cephalin, and synthetic phospholipids; the material used to modify the microparticles after encapsulating the active substance in the nanoneedle is selected from one or more of borneol, musk, styrax, and benzoin; the hydrogel precursor material in the nanoneedle is selected from one or more of polyvinyl alcohol (PVA), polylactic acid (PLA), polylactic acid-glycolic acid copolymer (PLGA), hyaluronic acid, chitosan, pectin, and sodium alginate.
[0007] Furthermore, the present invention provides a ziconopeptide nanoneedle for the treatment of chronic pain, which also has the following characteristics: the final concentration of the ziconopeptide in the hydrogel precursor solution is 20-50 mg / mL.
[0008] Furthermore, the present invention provides a ziconopeptide nanoneedle for the treatment of chronic pain, which also has the following characteristics: wherein the base thickness of the microneedle is 500μm to 1mm, the needle height is 400μm to 1000μm, and the needle base diameter is 20 to 400μm; the base side length of the square microneedle is 1.2 to 15cm, and the base diameter of the circular microneedle is 1.5 to 15cm.
[0009] Furthermore, the present invention provides a ziconopeptide nanoneedle for the treatment of chronic pain, which also has the following characteristics: wherein the microneedle is engraved with vertically intersecting easily divisible lines, dividing the microneedle into 4 equal parts.
[0010] This invention also provides a method for preparing the above-mentioned ziconopeptide nanoneedles for the treatment of chronic pain, comprising the following steps:
[0011] First, prepare nanoneedle molds with nanoneedle dimensions;
[0012] Second, ziconopeptide is thoroughly mixed with one or more of the following materials: distearylphosphatidylethanolamine, lecithin, soybean lecithin, cephalin, and synthetic phospholipids, to prepare microparticles of ziconopeptide encapsulated in the mixture.
[0013] The preparation method can be selected according to the specific type of the coating material, such as thin film evaporation, ultrasonic method, secondary emulsification method, reverse phase evaporation method, injection method, etc.
[0014] The microparticles of the encapsulated ziconopeptide prepared can be liposomes, nanoparticles, nanomicelles, etc.
[0015] Third, the above-mentioned microparticles are surface-modified using one or more of the following modifying materials: borneol, musk, styrax, and benzoin; wherein the preparation method can be selected according to the specific type of modifying material, such as thin film evaporation, ultrasonic method, secondary emulsification method, reverse phase evaporation method, or injection method.
[0016] The first and second steps mentioned above can be combined.
[0017] Fourth, the above-mentioned encapsulated and modified microparticles are mixed with one or more of polyvinyl alcohol, polylactic acid, polylactic acid-glycolic acid copolymer, hyaluronic acid, chitosan, pectin, and sodium alginate to prepare ziconopeptide precursor hydrogel.
[0018] Fifth, the above-mentioned ziconopeptide precursor hydrogel is poured into the mold prepared in the first step, and then cured (i.e., poured and cured) to obtain ziconopeptide nanoneedles.
[0019] The curing method can be selected according to the specific type of hydrogel precursor, such as drying, heating, photocrosslinking, or ionic crosslinking.
[0020] The advantages of this invention are:
[0021] The ziconopeptide nanoneedles prepared by the method of this invention for the treatment of chronic pain are a sustained-release drug delivery system that can exert drug efficacy. Its characteristic is that it changes the single drug delivery method of ziconopeptide in clinical practice, which can only be administered via intrathecal injection. The drug delivery method is more flexible and may not cause secondary trauma, other damage or other complications.
[0022] The ziconopeptide nanoneedles prepared by the method of the present invention for the treatment of chronic pain are encapsulated with one or more of the following materials: distearate phosphatidylethanolamine, lecithin, soybean phosphatidylcholine, cephalin, and synthetic phospholipids. This encapsulation can protect the stability of the ziconopeptide structure and ensure the stability of the drug efficacy.
[0023] The ziconopeptide nanoneedles prepared by the method of the present invention for the treatment of chronic pain are modified with one or more of the following materials: borneol, musk, styrax, and benzoin. This modification can facilitate the penetration of ziconopeptide-loaded microparticles through the blood-brain barrier and blood-spinal barrier, thereby exerting their therapeutic effects in the cerebrospinal fluid and throughout the body.
[0024] In addition, due to the toxicity of ziconovide, the dosage of ziconovide used in clinical applications increases with the duration of administration. The ziconovide nanoneedles prepared by the method of this invention for the treatment of chronic pain are engraved with vertically intersecting easily divisible lines, which can easily divide the microneedles into 4 equal parts to achieve different dosages at different stages. Specifically, in clinical use, during the first week of administration, a uniform 1 / 4 tablet of microneedles is taken each time; during the second week of administration, two uniform 1 / 4 tablets of microneedles are taken each time; and during administration after two weeks, the whole microneedle is taken each time. Attached Figure Description
[0025] Figure 1 A schematic diagram of the structure of the ziconopeptide nanoneedles prepared according to the preparation method of Example 1 of the present invention;
[0026] 1. Easy-tear marking line;
[0027] 2: Microneedle body;
[0028] 3: Microneedle base.
[0029] Figure 2 Schematic diagram of the encapsulation modification of ziconopeptide in nanoneedles;
[0030] 1: Ziconopeptide drug molecule;
[0031] 2: Packaging materials;
[0032] 3: Decorative materials;
[0033] 4: Hydrogel matrix.
[0034] Figure 3 A physical image of a Ziconopeptide nanoneedle, Example 2; Detailed Implementation
[0035] The present invention will be further described in detail below through embodiments, which are intended to illustrate the invention and not limit it. Furthermore, it should be particularly noted that those skilled in the art can make various improvements and modifications to the invention without departing from its principles, and these improvements and modifications also fall within the protection scope of the present invention.
[0036] Example 1: Preparation of a Ziconopeptide Nanoneedle
[0037] 1. Prescription (1000 tablets)
[0038]
[0039]
[0040] 2. Fabrication of nanoneedle molds with nanoneedle dimensions;
[0041] The dimensions of the Ziconopeptide microneedle patch were designed, with a base thickness of 500 μm, a needle height of 400 μm, and a needle base diameter of 20 μm. The microneedle patch was a square patch with a base side length of 1.2 cm. A microneedle mold was printed using 3D printing technology for later use.
[0042] 3. Preparation of nanoparticles loaded with ziconopeptide
[0043] Ziconopeptide-encapsulated nanoliposomes were prepared by thin-film dispersion. Lecithin, distearate phosphatidylethanolamine, and ziconopeptide were weighed in a ratio of 10:10:2 and dissolved together in a mixed solvent of chloroform and methanol. The co-solution was placed in a rotary evaporator and rotary evaporated at 40℃, 200 rpm, and 600 vacuum until all organic solvents were evaporated. After evaporation, the film in the flask was thoroughly mixed and dissolved with 10 mL of pure water and hydrated at 37℃ for 2 h. During the hydration process, sonication was performed for 1 min every 15 min. After hydration, ziconopeptide-encapsulated nanoliposomes were obtained.
[0044] 4. Surface modification of ziconopeptide nanoparticles
[0045] The surface of ziconopeptide-loaded nanoparticles was modified using a thin-film dispersion method. The ziconopeptide-loaded nanoliposomes and borneol were dissolved together in methanol at a ratio of 44:1. The co-solution was placed in a rotary evaporator and rotary evaporated at 37°C, 100 rpm, and 600°C until all organic solvents were evaporated. After evaporation, the film in the bottle was thoroughly dissolved with 10 mL of pure water and hydrated at 37°C for 2 h. During the hydration process, sonication was performed for 1 min every 15 min. After hydration, the modified ziconopeptide-loaded nanoliposomes were obtained.
[0046] 5. Preparation of a Ziconopeptide nanoneedle
[0047] Hydrogel nanoneedles loaded with modified zicosinate nanoliposomes were prepared using a two-stage casting method. Specifically, 37.5 g of hyaluronic acid was dissolved in 100 mL of water, and 40 g of chitosan was dissolved in 100 mL of methanol. The mixture was then stirred, and the modified zicosinate nanoliposomes were added. The methanol was evaporated to dryness using a rotary evaporator, and an appropriate amount of pure water was added to obtain the precursor. The rotary evaporator conditions were set at 37℃, 200 rpm, and 300°C vacuum. Subsequently, 500 μL of the precursor solution was dropped into a microneedle template and centrifuged at 3000 rpm for 30 min using a basket rotor to ensure complete penetration of the precursor solution into the microneedle template, forming the basic microneedle shape. The template was then subjected to a first heating and curing process. Then, another 300 μL of the precursor solution was dropped into the microneedle template and centrifuged at 3000 rpm for 30 min using a basket rotor to completely fill the template with the precursor solution. Excess solution was collected and reused. The microneedle template filled with precursor solution was cured in a vacuum dryer for 3 hours. After that, the template was peeled off and laser-engraved with vertically intersecting easily slicing lines to obtain a ziconopeptide nanoneedle for the treatment of chronic pain.
[0048] When using, simply apply the nano-microneedles directly to the affected area for localized chronic pain or to the appropriate location for systemic chronic pain.
[0049] Example 2: Preparation of a Ziconopeptide Nanoneedle
[0050] 1. Prescription (1000 tablets)
[0051]
[0052]
[0053] 2. Fabrication of nanoneedle molds with nanoneedle dimensions;
[0054] The dimensions of the Ziconopeptide microneedle patch were designed, with the microneedle base thickness set at 1 mm, needle height at 600 μm, and needle base diameter at 250 μm. The microneedle patch was a square patch with a base side length of 1.45 cm. A microneedle mold was printed using 3D printing technology for later use.
[0055] 3. Preparation of nanoparticles loaded with ziconopeptide
[0056] Ziconopeptide-encapsulated nanoliposomes were prepared by thin-film dispersion. Ziconopeptide, soybean lecithin, phosphatidylcholine, and distearate were weighed in a ratio of 5:5:10:5 and dissolved together in a mixed solvent of chloroform and methanol. The solution was placed in a rotary evaporator and rotary evaporated at 45°C, 200 rpm, and 1200°C vacuum until all organic solvents were evaporated. After evaporation, the film in the flask was thoroughly mixed and dissolved with 10 mL of pure water and hydrated at 37°C for 3 h. During the hydration process, sonication was performed for 1 min every 15 min. After hydration, ziconopeptide-encapsulated nanoliposomes were obtained.
[0057] 4. Surface modification of ziconopeptide nanoparticles
[0058] The surface of zicosinate-encapsulated nanoparticles was modified using a thin-film dispersion method. The zicosinate-encapsulated nanoliposomes and styrax were dissolved together in methanol at a ratio of 25:1. The co-solution was placed in a rotary evaporator and rotary evaporated at 37°C, 100 rpm, and 600°C vacuum until all organic solvents were evaporated. After evaporation, the film in the bottle was thoroughly mixed with 10 mL of pure water and hydrated at 37°C for 2 h. During the hydration process, sonication was performed for 1 min every 15 min. After hydration, the modified zicosinate-encapsulated nanoliposomes were obtained.
[0059] 5. Preparation of a Ziconopeptide nanoneedle
[0060] Hydrogel nanoneedles loaded with modified zicosinate nanoliposomes were prepared using a two-stage casting method. Specifically, 32g of hyaluronic acid was dissolved in 50mL of water, and 42g of chitosan was dissolved in 50mL of methanol. The mixture was then added to the methanol solution, and the methanol was evaporated to dryness using a rotary evaporator. A suitable amount of pure water was added to obtain the precursor. The rotary evaporator conditions were set at 37℃, 100rpm, and 450℃ vacuum. Subsequently, 500μL of the precursor solution was added dropwise to a microneedle template and centrifuged at 5000rpm for 20min using a basket rotor to ensure complete incorporation and the formation of the basic microneedle shape. Then, another 200μL of the precursor solution was added dropwise to the microneedle template and centrifuged at 5000rpm for 20min to completely fill the template with the precursor solution. Excess solution was collected and reused. The microneedle template filled with precursor solution was cured in a vacuum dryer for 5 hours, and then the template was peeled off to obtain a ziconopeptide nanoneedle for the treatment of chronic pain.
[0061] When using, simply apply the nano-microneedles directly to the affected area for localized chronic pain or to the appropriate location for systemic chronic pain.
[0062] Example 3: Preparation of a Ziconopeptide Nanoneedle
[0063] 1. Prescription (1000 tablets)
[0064]
[0065] 2. Fabrication of nanoneedle molds with nanoneedle dimensions;
[0066] The dimensions of the Ziconopeptide microneedle patch were designed, with the microneedle base thickness set at 0.8 mm, needle height at 1000 μm, and needle base diameter at 350 μm. The microneedle patch is circular, with a base side length of 5 cm. A microneedle mold was printed using 3D printing technology for later use.
[0067] 3. Preparation of nanoparticles loaded with ziconopeptide
[0068] Ziconopeptide-encapsulated nanoliposomes were prepared by thin-film dispersion. Ziconopeptide and lecithin were weighed in a 4:30 ratio and dissolved together in a mixed solvent of chloroform and methanol. The co-solution was placed in a rotary evaporator and rotary evaporated at 50℃, 100 rpm, and 500 vacuum until all organic solvents were evaporated. After evaporation, the film in the flask was thoroughly mixed and dissolved with 10 mL of pure water and hydrated at 37℃ for 2 h. During the hydration process, sonication was performed for 1 min every 15 min. After hydration, ziconopeptide-encapsulated nanoliposomes were obtained.
[0069] 4. Surface modification of ziconopeptide nanoparticles
[0070] The surface of ziconopeptide-loaded nanoparticles was modified using a thin-film dispersion method. The ziconopeptide-loaded nanoliposomes and borneol were dissolved together in methanol at a ratio of 34:1. The co-solution was placed in a rotary evaporator and rotary evaporated at 37°C, 200 rpm, and 500°C until all organic solvents were evaporated. After evaporation, the film in the bottle was thoroughly dissolved with 10 mL of pure water and hydrated at 37°C for 2 h. During the hydration process, sonication was performed for 1 min every 15 min. After hydration, the modified ziconopeptide-loaded nanoliposomes were obtained.
[0071] 5. Preparation of a Ziconopeptide nanoneedle
[0072] Hydrogel nanoneedles loaded with modified ziconopeptide nanoliposomes were prepared using a two-stage casting method. Specifically, 65g of sodium alginate was dissolved in 100mL of water, and the modified ziconopeptide-loaded nanoliposomes were added. The mixture was sheared at high speed for 30 minutes to ensure thorough mixing, and a suitable amount of pure water was added to obtain a precursor. Then, 300μL of the precursor solution was dropped into a microneedle template and centrifuged at 3000rpm for 20 minutes using a basket rotor to ensure complete penetration of the precursor solution into the microneedle template, forming the basic microneedle shape. The template was then subjected to a first heating and curing process. Subsequently, another 300μL of the precursor solution was dropped into the microneedle template and centrifuged at 3000rpm for 20 minutes using a basket rotor to completely fill the template with the precursor solution. Excess solution was collected and reused. The microneedle template filled with the precursor solution was then cured under vacuum for 5 hours in a vacuum dryer. Afterward, the template was peeled off to obtain ziconopeptide nanoneedles for the treatment of chronic pain.
[0073] When using, simply apply the nano-microneedles directly to the affected area for localized chronic pain or to the appropriate location for systemic chronic pain.
[0074] Example 4: Preparation of a Ziconopeptide Nanoneedle
[0075] 1. Prescription (1000 tablets)
[0076]
[0077] 2. Fabrication of nanoneedle molds with nanoneedle dimensions;
[0078] The dimensions of the Ziconopeptide microneedle patch were designed, with the microneedle base thickness set at 0.6 mm, needle height at 500 μm, and needle base diameter at 400 μm. The microneedle patch is a square patch with a base side length of 8 cm. A microneedle mold was printed using 3D printing technology for later use.
[0079] 3. Preparation of nanoparticles loaded with ziconopeptide
[0080] Ziconopeptide-encapsulated nanoliposomes were prepared by thin-film dispersion. Ziconopeptide and distearate phosphatidylethanolamine-PEG were weighed in a ratio of 3:25 and dissolved together in a mixed solvent of chloroform and methanol. The co-solution was placed in a rotary evaporator and rotary evaporated at 37°C, 100 rpm, and 600°C until all organic solvent was evaporated. After evaporation, the film in the flask was thoroughly mixed and dissolved with 10 mL of pure water and hydrated at 37°C for 1 h. During the hydration process, sonication was performed for 1 min every 15 min. After hydration, ziconopeptide-encapsulated nanoliposomes were obtained.
[0081] 4. Surface modification of ziconopeptide nanoparticles
[0082] The surface of ziconopeptide-loaded nanoparticles was modified using a thin-film dispersion method. The ziconopeptide-loaded nanoliposomes, borneol, and camphor were dissolved in a methanol-water (50:50) solution in a ratio of 28:1:1. The solution was placed in a rotary evaporator and subjected to rotary evaporation at 37°C, 100 rpm, and 600°C vacuum until all organic solvents were evaporated. After evaporation, the film in the bottle was thoroughly mixed with 10 mL of pure water and hydrated at 37°C for 1 h. During the hydration process, sonication was performed for 1 min every 15 min. After hydration, the modified ziconopeptide-loaded nanoliposomes were obtained.
[0083] 5. Preparation of a Ziconopeptide nanoneedle
[0084] Hydrogel nanoneedles loaded with modified zicosinate nanoliposomes were prepared using a two-stage casting method. Specifically, 30g of hyaluronic acid was dissolved in 50mL of water, and 20g of pectin was dissolved in 50mL of alkaline water. The mixture was then added to the modified zicosinate nanoliposomes, and a suitable amount of pure water was added and mixed thoroughly. The mixture was then sheared using a high-speed shear press, and the osmotic pressure was adjusted to obtain the precursor. Subsequently, 500μL of the precursor solution was dropped into a microneedle template and centrifuged at 3000rpm for 30min using a basket rotor to ensure complete penetration of the precursor solution into the template, forming the basic microneedle shape. The template was then subjected to a first heating and curing process. Following this, another 300μL of the precursor solution was dropped into the microneedle template and centrifuged at 3000rpm for 30min using a basket rotor to completely fill the template with the precursor solution. Excess solution was collected and reused. The microneedle template filled with precursor solution was dried in an oven for 12 hours to solidify, and then the template was peeled off to obtain a ziconopeptide nanoneedle for the treatment of chronic pain.
[0085] When using, simply apply the nano-microneedles directly to the affected area for localized chronic pain or to the appropriate location for systemic chronic pain.
[0086] Example 5: Preparation of a Ziconopeptide Nanoneedle
[0087] 1. Prescription (1000 tablets)
[0088]
[0089] 2. Fabrication of nanoneedle molds with nanoneedle dimensions;
[0090] The dimensions of the Ziconopeptide microneedle patch were designed, with a base thickness of 1 mm, a needle height of 750 μm, and a needle base diameter of 300 μm. The microneedle patch was a square patch with a base side length of 12 cm. A microneedle mold was printed using 3D printing technology for later use.
[0091] 3. Preparation and modification of nanoparticles loaded with ziconopeptide
[0092] Ziconopeptide-encapsulated and modified nanoliposomes were prepared by thin-film dispersion. Ziconopeptide, soybean lecithin, and cephalin were weighed in a ratio of 5:15:5 and dissolved together in a mixed solvent of chloroform and methanol. The co-solution was placed in a rotary evaporator and rotary evaporated at 40℃, 200 rpm, and 800 vacuum until all organic solvents were evaporated. After evaporation, the film in the bottle was thoroughly mixed and dissolved with 10 mL of pure water and hydrated at 37℃ for 4 h. During the hydration process, sonication was performed for 1 min every 15 min. After hydration, nanoliposomes encapsulated with ziconopeptide were obtained.
[0093] 4. Preparation of a Ziconopeptide nanoneedle
[0094] Hydrogel nanoneedles loaded with modified ziconopeptide nanoliposomes were prepared using a two-stage casting method. Specifically, 74.2 g of hyaluronic acid was dissolved in 90 mL of water, and the modified ziconopeptide-loaded nanoliposomes were added to the solution along with an appropriate amount of purified water. The mixture was thoroughly sheared and mixed to obtain a precursor. Then, 500 μL of the precursor solution was dropped into a microneedle template and centrifuged at 5000 rpm for 40 min using a basket rotor to ensure complete penetration and the formation of the basic microneedle shape. The template was then subjected to a first heating and curing process. Subsequently, another 200 μL of the precursor solution was dropped into the microneedle template and centrifuged at 5000 rpm for 40 min to completely fill the template with the precursor solution. Excess solution was collected and reused. The microneedle template filled with the precursor solution was then cured under vacuum for 5 hours in a vacuum dryer. Afterward, the template was peeled off to obtain ziconopeptide nanoneedles for the treatment of chronic pain.
[0095] When using, simply apply the nano-microneedles directly to the affected area for localized chronic pain or to the appropriate location for systemic chronic pain.
[0096] Experimental Example 1: Study on the in vitro skin insertion capability of a ziconopeptide nanoneedle of the present invention
[0097] The in vitro skin-penetration capability of the ziconopeptide nanoneedles was evaluated using abdominal skin from SD rats. The microneedles used in this experiment were those prepared in Example 2. First, abdominal skin from SD rats was removed, hair was removed, and the skin was fixed to a foam board. The ziconopeptide nanoneedles of this invention were placed on the skin with the needle tips facing down, and pressure was applied with the thumb for 2 minutes. Subsequently, the microneedles were removed, the skin surface was wiped clean with physiological saline, and the saline was aspirated. The number of punctures left by the microneedles was observed and recorded using a magnifying glass. The insertion ratio was calculated based on the number of punctures left on the skin and the number of needles on the microneedle patch. Simultaneously, the depth of microneedle insertion into the skin was observed, analyzed, and recorded using tissue cryosectioning and ImageJ software.
[0098] The results showed that, after the ziconopeptide nanoneedles of Example 2 of this invention were inserted into the skin for 2 minutes, the number of puncture sites observed and recorded using a magnifying glass was completely consistent with the number of needles on the microneedle patch, indicating that all microneedles were inserted into the skin, with an insertion ratio of 100%. Furthermore, the depth of insertion into the skin, observed and analyzed using tissue cryosectioning technology and ImageJ software, was approximately 300 μm. This depth penetrates the stratum corneum and reaches the dermis, meaning that the ziconopeptide nanoneedles of this invention have sufficient mechanical strength to penetrate the stratum corneum and promote transdermal drug delivery.
[0099] Experimental Example 2: Study on the in vitro microneedle dissolution behavior of a ziconopeptide nanoneedle of the present invention
[0100] This invention relates to a ziconopeptide nanoneedle, which is a hydrogel nanoneedle with a soluble needle body. Therefore, an in vitro dissolution experiment was conducted using SD rat skin. The microneedles used in this experiment were those prepared in Example 2. First, abdominal skin was removed from SD rats, the hair was removed, and the skin was fixed to a foam board. The ziconopeptide nanoneedle of this invention was placed on the skin with the needle tip facing down. After pressing with the thumb for different durations, the microneedle was removed, and the morphological changes were observed using a stereomicroscope. The changes in the size of the microneedle were analyzed using ImageJ software.
[0101] The results showed that the dissolution rate of the ziconopeptide nanoneedles in Example 2 of this invention increased with the duration of skin insertion. After 1 minute of insertion, the microneedles dissolved rapidly, with an overall dissolution rate of approximately 30% of the total needle mass. After 2 minutes, the microneedles dissolved rapidly, with an overall dissolution rate of approximately 50% of the total needle mass. After 3 minutes, the dissolution rate slowed, with an overall dissolution rate of approximately 58% of the total needle mass. After 4 minutes, the dissolution rate decreased further, with an overall dissolution rate of approximately 61% of the total needle mass. After 6 minutes, the overall dissolution rate was approximately 63% of the total needle mass. After 6 minutes, the microneedles entered a sustained-release phase, achieving a long-lasting drug release effect while rapidly reaching the therapeutic window.
[0102] Experimental Example 3: Study on the in vitro drug release behavior of a ziconopeptide nanoneedle of the present invention
[0103] The in vitro drug release behavior of the ziconopeptide nanoneedles of this invention was determined using a transdermal diffusion cell. The microneedles used in this experiment were those prepared in Example 2. The ziconopeptide nanoneedles were attached to a medical tape of a specific size, with the microneedle base in contact with the tape. The needles were placed on the skin of SD rats treated as described above, with the needle tips facing down. Thumb pressure was applied for 2 minutes, and then the needles were immediately transferred to a pre-prepared Franz transdermal diffusion cell and placed in a transdermal diffusion apparatus. The receiving cell contained 7.1 mL of PBS buffer, the temperature was set to 32°C, and the rotor speed was set to 250 rpm. At 5, 10, 30, and 60 minutes of operation of the transdermal diffusion apparatus, 1 mL of liquid was taken from the receiving cell of the diffusion cell, and 1 mL of replenishing solution was added. After all sampling was completed, the content of ziconopeptide at each point was determined by high-performance liquid chromatography (HPLC), and the cumulative release was calculated.
[0104] The results showed that: in the first 5 minutes after the ziconopeptide nanoneedles of Example 2 of the present invention were inserted into the skin, ziconopeptide was released rapidly, with a cumulative release of about 40%; at 10 minutes after the microneedles were inserted into the skin, the release rate was still fast, with a cumulative release of about 60%; at 30 minutes after the microneedles were inserted into the skin, the cumulative release of ziconopeptide reached about 80%; and at 60 minutes after the microneedles were inserted into the skin, the cumulative release of ziconopeptide reached nearly 100%.
[0105] Experimental Example 4: Study on the safety and tissue irritation of the ziconopeptide nanoneedles of the present invention in rats.
[0106] The microneedles used in this experiment were those prepared in Example 2. Male SD rats (weighing 200–250 g) were randomly divided into four groups using a random number table: (1) intrathecal injection of zicosome peptide, (2) transdermal administration of zicosome peptide microneedles, (3) oral administration of morphine, and (4) transdermal administration of microneedle matrix. Each group consisted of six rats. The rats were administered the drugs listed in the group settings orally, intrathecally, or transdermally. After administration, the rats were kept for a certain period, and their behavior and survival status were observed. The injection volume for all injection groups was 10 μL, and the gavage volume for all gavage groups was 200 μL. The rats were then sacrificed, and brain, heart, liver, spleen, lung, and kidney tissues were collected for H&E staining to observe and compare the pathological states of each tissue.
[0107] The results showed that no SD rats in any group died after administration, indicating that the ziconopeptide nanoneedles of Example 2 of this invention have the same good safety as the control group. Histopathological results showed that the ziconopeptide nanoneedles of Example 2 of this invention did not show obvious lymphocyte infiltration, tissue damage, or necrosis after administration, further demonstrating the good safety of the ziconopeptide nanoneedles of this invention.
[0108] Experimental Example 5: Pharmacodynamic Study of a Ziconopeptide Nanoneedle of the Present Invention
[0109] The microneedles used in this experiment were those prepared in Example 2. SPF-grade SD rats, weighing 200–250 g, were selected. The model was established according to the literature reported by HBJia et al. Rats were anesthetized with urethane via intraperitoneal injection at 1500 mg / kg. The rats were fixed prone on the operating table with a thin pad under their abdomen. The area was shaved and disinfected. An incision was made along the midline of the L4-6 spine, and the muscle tissue on the right side of the spine was bluntly dissected. The L5 transverse process was removed, exposing and identifying the L5 spinal nerve. The right L5 spinal nerve was ligated and severed with 3-0 silk suture, and the incision was sutured and closed. The sham-operated group underwent the same procedure as the surgical group, except that the L5 spinal nerve was not severed. During the operation and postoperative recovery, the rats were kept warm with a constant-temperature electronic heating blanket. From day 7 to 14 postoperatively, different groups received drug intervention, administered daily from 7:00 to 8:00 AM.
[0110] Male SD rats (weighing 200–250 g) were randomly divided into the following groups using a random number table, with 6 rats in each group: (1) Sham-operated group (sham surgery + oral and intraperitoneal injection of equal volume of physiological saline), (2) L5SNT group (L5 spinal nerve transection + oral and intraperitoneal injection of equal volume of physiological saline), (3) Ziconotide injection group (L5SNT + intrathecal injection of ziconotide), and (4) High-concentration ziconotide microneedle administration group (L5SNT + ziconotide microneedle administration with a drug release dose of approximately 20 mg / d). (5) Medium concentration group of ziconovide microneedle administration (L5SNT + ziconovide microneedle administration, drug release dose approximately 10 mg / d), (6) Low concentration group of ziconovide microneedle administration (L5SNT + ziconovide microneedle administration, drug release dose approximately 5 mg / d), (7) Microneedle matrix group (L5SNT + blank microneedle transdermal administration), (8) Morphine group (L5SNT + morphine 10 mg / kg). The injection volume of all injection groups was 10 uL, and the gavage volume of all gavage groups was 200 uL. Drug intervention was started on the 7th day after surgery in all rats and continued for 7 days.
[0111] The heat-induced paw withdrawal latency was measured on day 3 before modeling, on the day of modeling, and 6 hours after the start of drug administration on day 7 after modeling. A plantar irradiation device was used to detect the skin response of the rat hind limb heel to heat-induced damage. The heat stimulation intensity was designed to induce a paw withdrawal response approximately 15 seconds after exposure to light, typical of normal rats. To prevent tissue damage from prolonged heat stimulation, the heat source was automatically shut off after 20 seconds. During the experiment, the paw withdrawal latency was measured three times on each side of the rats every 5 minutes. The average of the three paw withdrawal latency measurements was taken and statistically analyzed.
[0112] The results showed that before modeling, the heat stimulation withdrawal latency of all SD rats was approximately 10.0 s. After modeling, the heat stimulation withdrawal latency in the sham-operated group (sham surgery + oral and intraperitoneal injection of equal volume of physiological saline) remained approximately 10.0 s, while that in all surgical groups decreased to 7.5 s. Drug administration began 7 days after modeling, and the heat stimulation withdrawal latency of each group was measured again before administration; the results essentially maintained the post-modeling latency. Drug administration was performed according to the experimental settings. The heat stimulation withdrawal latency of the rats was measured again 6 hours after administration. The heat stimulation withdrawal latency in the sham-operated group remained approximately 10.0 s, while that in the modeling group was approximately 7.0 s. The heat stimulation withdrawal latency increased in all drug administration groups. Specifically, the ziconopeptide injection group (L5SNT + intrathecal ziconopeptide injection) had a latency of approximately 14.0 s, and the high-concentration ziconopeptide microneedle administration group (L5SNT + ziconopeptide microneedle administration with a drug release dose of approximately 20 mg / d) had a latency of approximately 14.0 s. The time to delivery of the microneedle matrix group (L5SNT + ziconovide microneedle delivery dose of approximately 10 mg / d) was approximately 17.0 s, the time to delivery of the low concentration group (L5SNT + ziconovide microneedle delivery dose of approximately 5 mg / d) was approximately 14.0 s, the time to delivery of the microneedle matrix group (L5SNT + blank microneedle transdermal delivery) was approximately 7.5 s, and the time to delivery of the morphine group (L5SNT + morphine 10 mg / kg) was approximately 12.5 s. This indicates that the microneedle matrix, lacking ziconovide, does not possess analgesic effects. Both ziconovide and morphine are effective in relieving and treating chronic pain, with ziconovide exhibiting stronger pharmacological effects than morphine. Furthermore, the pharmacological effects of the low, medium, and high dose groups of the ziconovide nanoneedles of this invention show a concentration-dependent effect; within a certain range, the higher the dose, the better the therapeutic effect on chronic pain. At this dosage, the effect is superior to that of the intrathecal ziconovide injection group. This demonstrates that the ziconovide nanoneedles of Example 2 of this invention have good effects in relieving and treating chronic pain.
Claims
1. A ziconopeptide nanoneedle, characterized in that, The ziconopeptide nanoneedles are hydrogel nanoneedles with ziconopeptide nanoliposome microparticles loaded on the needle tip and modified on the surface. The ziconopeptide nanoneedles, prepared in quantities equivalent to 1000 tablets, consist of: 5 g ziconopeptide, 5 g soybean lecithin, 10 g lecithin, 5 g distearate phosphatidylethanolamine, 1 g styrax, 32 g hyaluronic acid, and 42 g chitosan. The ziconopeptide, soybean lecithin, lecithin, and distearate phosphatidylethanolamine are used to prepare nanoliposomes encapsulated with ziconopeptide. The styrax is used to modify the surface of the nanoliposomes. The hyaluronic acid and chitosan are used to form the precursor matrix of the ziconopeptide nanoneedles. The microneedle has a base thickness of 1 mm, a needle height of 600 μm, a needle bottom diameter of 250 μm, and a square patch with a base side length of 1.45 cm.
2. The ziconopeptide nanoneedles according to claim 1, characterized in that, The nanoliposomes loaded with ziconopeptide were prepared by thin-film dispersion and hydrated at 37°C for 3 h, with sonication for 1 min every 15 min during the hydration process.
3. The ziconopeptide nanoneedles according to claim 1, characterized in that, The surface modification was carried out using a thin film dispersion method. The nanoliposomes loaded with ziconopeptide were dissolved together with styrax in methanol. After rotary evaporation at 37°C, 100 rpm and a vacuum of 600, they were mixed with 10 mL of pure water and dissolved. The mixture was then hydrated at 37°C for 2 h, with sonication for 1 min every 15 min during the hydration process.
4. The ziconopeptide nanoneedles according to claim 1, characterized in that, The precursor was obtained as follows: 32 g of hyaluronic acid was dissolved in 50 mL of water, and 42 g of chitosan was dissolved in 50 mL of methanol. After mixing the two, nano-liposomes loaded with ziconopeptide that had been surface modified were added. The methanol was evaporated at 37°C, 100 rpm and a vacuum of 450°C, and then an appropriate amount of pure water was added to obtain the precursor.
5. A method for preparing ziconopeptide nanoneedles according to any one of claims 1-4, characterized in that, Includes the following steps: (1) Preparation of nanoneedle molds; (2) Weigh out ziconopeptide, soybean lecithin, lecithin and distearate phosphatidylethanolamine in a mass ratio of 5:5:10:5, dissolve them together in a mixed solvent of chloroform and methanol, and rotary evaporate at 45℃, 200 rpm and vacuum degree of 1200 until the organic solvent is completely evaporated; after evaporation, mix with 10 mL of pure water and hydrate at 37℃ for 3 h, sonicate for 1 min every 15 min during hydration to obtain nanoliposome microparticles loaded with ziconopeptide; (3) Dissolve the nanoliposomes loaded with ziconopeptide and styrax in methanol at a mass ratio of 25:
1. Rotary evaporate at 37°C, 100 rpm and 600°C until the organic solvent is completely evaporated. After evaporation, mix with 10 mL of pure water and hydrate at 37°C for 2 h. During the hydration process, sonicate for 1 min every 15 min to obtain the surface-modified nanoliposomes loaded with ziconopeptide. (4) Dissolve 32 g of hyaluronic acid in 50 mL of water and 42 g of chitosan in 50 mL of methanol. Mix the two together and add the surface-modified nanoliposomes loaded with ziconopeptide obtained in step (3). Evaporate the methanol at 37°C, 100 rpm and a vacuum of 450°C, and add an appropriate amount of pure water to obtain the precursor. (5) Drop 500 μL of precursor solution into the microneedle template and centrifuge at 5000 rpm for 20 min to allow the precursor solution to enter the microneedle template and form a microneedle body prototype. Then, 200 μL of precursor solution was added dropwise into the microneedle template, and the template was centrifuged at 5000 rpm for 20 min to fill the microneedle template with precursor solution. (6) The microneedle template filled with precursor solution was solidified in a vacuum dryer for 5 h, and the template was peeled off to obtain ziconopeptide nanoneedles.
6. The use of the ziconopeptide nanoneedles according to any one of claims 1-4 in the preparation of a medicament for transdermal administration of chronic pain.
Citation Information
Patent Citations
Soluble microneedle containing ingredient for controlling release of neurotransmitters
CN107427474A
Local analgesic microneedle device for neuropathic pain and preparation method thereof
CN108553408A
Microneedle for transdermal administration and preparation method thereof
CN110812688A
